Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Julie Kim
Person

Julie Kim

Tracked across 1 events · 21 articles · First seen Aug 05, 2026 · Last active Aug 19, 2026

Sentiment
50
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
6 50
Regulatory
FDA Approves Takeda's Orzeyful for Narcolepsy Type 1
The U.S. United States — Food and Drug Administration (FDA) approved Takeda Pharmaceutical Company's Orzeyful (oveporexton) as the first oral orexin receptor 2 agonist for the treatment of narcolepsy type 1 (NT1) in adults. This…
Impact: As Takeda's president and CEO, Julie Kim celebrated the approval as a new chapter for the NT1 community and reaffirmed the company's commitment to bringing the drug to patients quickly.
Aug 05, 2026 · 21 articles
ERGEN INTELLIGENCE
Track Julie Kim live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.